A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

References

• JessupMBrozenaSHeart failureN Engl J Med20033482007201812748317
   PubMed Web of Science ®Google Scholar
• MassieBMArmstrongPWClelandJGToleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure: Results from the Atlas trialArch Intern Med2001161216517111176729
   PubMedGoogle Scholar
• CohnJNTognoniGValsartan Heart Failure Trial InvestigatorsRandomized trial of the angiotensin receptor blocker, valsartan, in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• GrangerCBErtlGKuchJRandomized trial of candesartan in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitorsAm Heart J200013960961710740141
   PubMed Web of Science ®Google Scholar
• BlakeJDeveruxRVDifferential effects of direct antagonism of AII receptor blockers compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failureCongestive Heart Fail20006193196
   PubMedGoogle Scholar
• BakrisGSiomosMRichardsonDACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failureKidney Int2000582084209211044229
   PubMed Web of Science ®Google Scholar
• PrestonRABaltodanoNMAlonsoABEpsteinMComparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type 2 diabetes mellitusJ Clin Pharmacol20024275476112092742
   PubMed Web of Science ®Google Scholar
• PackerMCoatsAJSFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med20013441651165811386263
   PubMed Web of Science ®Google Scholar
• PittBRemmWZannadFThe effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med199934170971710471456
   PubMed Web of Science ®Google Scholar
• PittBRemmWZannadFEplerenone post acute myocardial infarction heart failure efficacy and survival study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med20033481309132112668699
   PubMed Web of Science ®Google Scholar
• AhmedAAmerican College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: Relevance to the geriatric practiceAm J Geriatr Soc200351123126
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkWRFor Collaborative Study GroupRenoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• CadnapaphornchaiMAMcFannKStrainJDMasoumiASchrierRWProspective change in renal volume and function in children with ADPKDClin J Am Soc Nephrol20094482082919346430
   PubMed Web of Science ®Google Scholar
• NutaharaKHigashiharaEHorieSCalcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney diseaseNephron Clin Pract20059911823
   Google Scholar
• KannoYOkadaHYamajiYNakazatoYSuzukiHAngiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentationQJM200598319920315728401
   PubMed Web of Science ®Google Scholar
• LiPKLeungCBChowKMFor HKVIN Study GroupHong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind randomized, placebo-controlled studyAm J Kidney Dis200647575176016632013
   PubMed Web of Science ®Google Scholar
• TaalMBrennerBCombination ACEI and ARB therapy: Additional benefit in renoprotectionCurr Opin Nephrol Hypertens20001137738112105385
   PubMed Web of Science ®Google Scholar
• SeguraJPragaMRodicioJLRuilopeLMCombination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended dosesJ Renin Angiotensin Aldosterone Syst20034434712692753
   PubMed Web of Science ®Google Scholar
• DillonJLAngiotensin converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathySemin Nephrol20042421822415156527
   PubMed Web of Science ®Google Scholar
• The ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• KnollGASaghagalANairRCGrhahmJRenin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patientsAm J Med200211211011411835948
   PubMed Web of Science ®Google Scholar
• FangJModhavanSCohenHAldermanMHSerum potassium and cardiovascular mortalityJ Gen Intern Med2000158850890
   Web of Science ®Google Scholar
• CharytanDGoldfarbDIndications for hospitalization of patients with hyperkalemiaArch Intern Med20001601605161110847253
   PubMedGoogle Scholar
• WinkelmayerWCZhangZShainfarSEfficacy and safety of angiotensin II receptor blockade in elederly patients with diabetesDiabetes Care2006292210221717003295
   PubMed Web of Science ®Google Scholar
• AppelGBRadhkrishnanJAvramMAnalysis of metabolic parameters as predictors of risk in the RENAAL studyDiabetes Care200361402140712716796
   PubMed Web of Science ®Google Scholar
• DonBRSebastianACheitlinMChristiansenMSchambelanMPseudohyperkalemia caused by fist clenching during phlebotomyN Engl J Med1990322129012922325722
   PubMed Web of Science ®Google Scholar
• ShlipakMGPharmacology of heart failure in patients with renal insufficiencyAnn Intern Med200313891792412779302
   PubMed Web of Science ®Google Scholar
• HeywoodTFonarowGCostanzoMMathurVHigh prevalence of renal dysfunction and its impact on outcome in 118465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE data baseJ Card Fail20071342243017675055
   PubMed Web of Science ®Google Scholar
• JuurlinkDNMamdaniMMLeeDSRates of hyperkalemia after publication of randomized aldactone evaluation studyN Engl J Med200435154355115295047
   PubMed Web of Science ®Google Scholar
• PalmerBFCurrent concepts: Managing hyperkalemia caused by inhibitors of the renin angiotensin aldosterone systemN Engl J Med200435154355115295047
   PubMed Web of Science ®Google Scholar
• TakaichiKTakemotoFUbaraYMoriYAnalysis of factors causing hyperkalemiaIntern Med20074682382917575373
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJfor the Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003491893190614610160
   PubMed Web of Science ®Google Scholar